Last reviewed · How we verify

NCT05580614

Paired tVNS With ERP in OCD

Recruiting now NA Last updated 27 October 2025
What this trial tests

NA trial testing Sham in OCD in 56 participants. Currently enrolling.

Timeline
27 June 2022
Primary endpoint
30 April 2026
31 August 2026

Quick facts

Lead sponsorUniversity of Florida
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment56
Start date27 June 2022
Primary completion30 April 2026
Estimated completion31 August 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Florida

Who can join

Adults 18 to 55, any sex, with OCD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In the proposed investigation, the investigator will develop pilot data for the use of tVNS (transcutaneous vagal nerve stimulation) to enhance efficacy of exposure and response prevention therapy (ERP) to improve treatment success in patients with OCD. This data will include tolerability information from therapists and patients with OCD, effect sizes on real world clinical outcomes for the combinatory treatment, and mechanistic data on brain changes associated with treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Sham

Trials testing the same drug.

Other recruiting trials for OCD

Currently open trials in the same condition.

Other University of Florida trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05580614.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing